BioInvent International AB (LTS:0H22)
kr 45.15 0 (0%) Market Cap: 2.84 Bil Enterprise Value: 1.80 Bil PE Ratio: 0 PB Ratio: 2.59 GF Score: 51/100

Q4 2021 BioInvent International AB Earnings Call Transcript

Feb 23, 2022 / 01:00PM GMT
Release Date Price: kr33.8
Martin Welschof;publ;CEO
BioInvent International AB

()-

Thank you very much, and welcome, everybody, to our quarterly call. And I would like to start with a brief summary of the events that happened during the last quarter.

So, we had positive interim data from our lead program, BI-1206 in non-Hodgkin lymphoma, where we could see increased and sustained responses in relapsed patients. And that was particular very impressive in follicular lymphoma. And then at the same time also, we released the positive early clinical data from BI-1206 in combination with pembrolizumab for solid tumors.

We also made good progress in our collaboration with CASI Pharmaceuticals. So, we received the IND for China for clinical studies in China at the end of last year. And then we also -- we are very proud that we advanced to the Nasdaq Stockholm mid-cap segment. And last but not least, we also got an orphan drug designation granted for BI-1206, which was very important also from a strategic clinical development perspective, and we got that for follicular lymphoma.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot